{"id":"W4322775169","doi":"10.1158/1538-7445.sabcs22-pd11-09","title":"Abstract PD11-09: PD11-09 Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Université de Sherbrooke; London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Internal medicine; Oncology; Triple-negative breast cancer; Tolerability; Cancer; Breast cancer; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009647208,0.0004945707,0.0007099011,0.0002569457,0.0001304714,0.000864425,0.0005034942,0.0003711407,0.00591522],"category_scores_gemma":[0.0005942777,0.0002044519,0.000749719,0.0003840141,0.0001912053,0.0003890299,0.0002189578,0.001280668,0.001031169],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001179844,"about_ca_system_score_gemma":0.0008548545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001650973,"about_ca_topic_score_gemma":0.005826679,"domain_scores_codex":[0.9996643,0.0001393401,0.00002334034,0.00005582262,0.00007508597,0.00004206085],"domain_scores_gemma":[0.9996933,0.00006601092,0.00009722068,0.00002281046,0.00004056945,0.0000802107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2163642,0.004951193,0.02276892,0.00371444,0.003833025,0.0002982065,0.0001357934,0.004812543,0.05135145,0.0008211367,0.06275224,0.6281969],"study_design_scores_gemma":[0.3108236,0.199204,0.1892133,0.001564226,0.01028631,0.002205095,0.0002300498,0.006879849,0.03648977,0.001671368,0.24126,0.0001725708],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8595424,0.07312587,0.002413168,0.003665079,0.0006748677,0.00181002,0.03412231,0.0004808717,0.02416548],"genre_scores_gemma":[0.9328846,0.01701562,0.002095587,0.003320837,0.0001886514,0.0006242184,0.03633901,0.00006690514,0.007464635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00591522,"threshold_uncertainty_score":0.01978838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1129856912723048,"score_gpt":0.4654116590674529,"score_spread":0.3524259677951481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}